U.S. Markets open in 7 hrs 25 mins

Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress

Glucagon pen NDA accepted for review by FDA

Continuing to execute commercial build and launch readiness for glucagon pen

Advancing pipeline of preclinical and clinical development-stage products  

CHICAGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced financial results for the third quarter ended September 30, 2018, as well as pipeline and corporate highlights.

“A major achievement in the third quarter was the planned submission to the FDA of our NDA for the glucagon pen for the treatment of severe hypoglycemia.  With a PDUFA goal date of June 10, 2019, we are actively preparing for a commercial launch in the US in the fourth quarter of 2019,” said Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals. “In addition, we continue to advance several other preclinical and clinical programs for which we anticipate topline data in the first half of 2019.”

Third Quarter 2018 Highlights and Recent Events

  • Glucagon pen NDA accepted for review by FDA: As previously announced, the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) of Xeris’ lead product candidate, glucagon pen, for the treatment of severe hypoglycemia in people with diabetes. The FDA has assigned a PDUFA goal date of June 10, 2019. (Severe hypoglycemia is characterized by sweating, trembling, anxiousness, confusion, and combativeness, often requiring external assistance for recovery. These events can be extremely frightening for patients and caregivers and can result in seizure or coma, and, if left untreated, death.) 
  • Strengthened commercial organization: Xeris has hired key commercial leadership personnel in areas of U.S. Marketing and Sales, Global Commercialization and Business Development to begin market preparation, launch readiness, ex-US commercial plans and partnering.
  • New Investigational New Drug (IND) application enables Phase 2 trial of ready-to-use glucagon for post-bariatric hypoglycemia (PBH): A new glucagon IND went into effect and authorized Xeris to proceed with a Phase 2 study with its ready-to-use, room-temperature stable liquid glucagon formulation for patients who experience hyperinsulinemic hypoglycemia after bariatric surgery. Xeris expects to initiate the study before the end of 2018. (PBH can begin to occur one to eight years after gastric bypass surgery. These severe hypoglycemic episodes are characterized by extreme low blood sugar levels that occur two to three hours after a meal. The etiology appears to be excessive insulin secretion in response to the meal.)
  • Concluded Phase 2 clinical trial in congenital hyperinsulinism (CHI) (NCT02937558). Xeris recently concluded enrollment in the Phase 2 study and expects the randomized controlled data will support initiation of a Phase 3 program for continuous subcutaneous infusion of glucagon for the treatment of congenital hyperinsulinism. (CHI is a very rare disease that causes severe, persistent hypoglycemia in newborn babies and children. Common symptoms include irritability, sleepiness, lethargy, excessive hunger, and rapid heart rate. More severe symptoms such as seizures and coma can occur with a prolonged or extremely low blood sugar level.)
  • Xeris room-temperature liquid stable glucagon used in artificial pancreas trial: In August, Xeris announced that OHSU School of Medicine and OHSU Harold Schnitzer Diabetes Health Center in Portland, Oregon are conducting a clinical trial with a dual-hormone artificial pancreas using Xeris’ ready-to-use liquid glucagon to evaluate a new closed-loop algorithm before and after exercise. (The artificial pancreas is a technology in development to help people with diabetes automatically control their blood glucose level by providing the substitute endocrine functionality of a healthy pancreas.)

Upcoming Events

  • Xeris will present three abstracts at the upcoming 18th Annual Diabetes Technology Meeting from November 8-10, 2018 in North Bethesda, Maryland.
  • Xeris’ senior management will be participating in the following upcoming investor conferences:
    • Jefferies London Healthcare Conference on November 14-15, 2018 in London, UK
    • Global Mizuho Investor Conference on December 3-4, 2018 in New York, NY

Third Quarter 2018 Financial Highlights

Cash position: As of September 30, 2018, Xeris reported total cash, cash equivalents, and short-term investments (collectively, “cash and investments”) of $131.0 million, compared to $42.0 million at December 30, 2017. Xeris’ cash and investments at September 30, 2018 included $15.0 million from the Company’s draw-down in the third quarter of the second tranche of its Loan and Security Agreement. The second tranche was contingent on the Company submitting the glucagon pen NDA prior to September 30, 2018.  The Company’s cash and investments at September 30, 2018 also included the $89.0 million in net proceeds from the Company’s initial public offering completed in June 2018.

Research and development (R&D) expenses: R&D expenses for the three months and nine months ended September 30, 2018 were $10.9 million and $28.3 million, respectively, compared to $5.7 million and $13.6 million for the same periods in 2017. The increases for both the three-month and nine-month periods were primarily due to increased product development expenses in support of the glucagon pen NDA filing and additional pipeline programs, as well as increased personnel expenses.  Additionally, the increase for the nine-month period was due to increased expenses associated with clinical programs and trials.  

General and administrative (G&A) expenses: G&A expenses for the three months and nine months ended September 30, 2018 were $4.7 million and $12.4 million, respectively, compared to $2.0 million and $4.9 million for the same periods in 2017. The increases were due to additional headcount and other employee-related costs, as well as increased marketing and market research expenses.

Net loss: For the three and nine months ended September 30, 2018, Xeris reported a net loss of $14.8 million, or $0.71 per share, and $39.7 million, or $4.36 per share, respectively, compared to a net loss of $7.5 million, or $3.72 per share, and $17.4 million, or $8.63 per share, for the same periods in 2017.

About Xeris Pharmaceuticals, Inc.
Xeris is a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use, room-temperature stable injectable and infusible drug formulations. The Company’s proprietary XeriSol™ and XeriJect™ formulation technologies are being evaluated for the subcutaneous (SC) and intramuscular (IM) delivery of highly-concentrated, non-aqueous, ready-to-use formulations of peptides, small molecules, proteins, and antibodies using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. XeriSol™ and XeriJect™ have the potential to offer distinct advantages over existing formulations of marketed and development-stage products, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. These attributes may lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system. Further information about Xeris can be found at www.xerispharma.com.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Xeris Pharmaceuticals, Inc., including statements concerning the timing or likelihood of approval by the FDA of its NDA for its glucagon pen, the market and therapeutic potential of its product candidates, the timing or likelihood of commercialization of our product candidates, the potential utility of its formulation platforms and other statements containing the words "will," "would," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, without limitation, the regulatory approval of its product candidates, its ability to market and sell its products, if approved, and other factors discussed in the "Risk Factors" section of the most recently filed Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Xeris’ subsequent filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Xeris expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications

Media Contact

(in thousands, except share and per share data; unaudited)
    Three Months Ended
September 30,
  Nine Months Ended
September 30,
      2018       2017       2018       2017  
Grant income   $   582     $   170     $   1,611     $   1,073  
Service revenue       -          -          53         16  
Cost of revenue       -          -          42         4  
  Gross profit       582         170         1,622         1,085  
Operating expenses:                
Research and development       10,875         5,725         28,264         13,588  
General and administrative        4,650         2,017         12,388         4,917  
  Expense from operations       15,525         7,742         40,652         18,505  
Loss from operations       (14,943 )       (7,572 )       (39,030 )       (17,420 )
Other income (expense):                
Interest income       462         45         796         45  
Interest expense       (737 )       -          (1,490 )       (1 )
Change in fair value of warrants       451         -          63         (32 )
  Total other income (expense)       176         45         (631 )       12  
Net loss   $   (14,767 )   $   (7,527 )   $   (39,661 )   $   (17,408 )
Net loss per common share - basic and diluted   $   (0.71 )   $   (3.72 )   $   (4.36 )   $   (8.63 )
Weighted average common shares
  outstanding, basic and diluted
      20,714,475         2,024,355         9,104,491         2,016,112  


(in thousands)  
    September 30, 2018      
      December 31, 2017  
Current assets:          
Cash and cash equivalents   $   75,745    $   42,045     
Short-term investments       55,296       
Accounts receivable, net       1,731        1,199     
Prepaid expenses and other current assets       2,898        809     
  Total current assets       135,670        44,053     
Property and equipment, net       1,826        788     
Other assets       95        157     
  Total assets   $   137,591    $   44,998     
Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)          
Current liabilities:          
Accounts payable   $   622   $   1,976    
Accrued expenses       6,260       2,557    
Warrant liabilities       1,042       93    
Deferred grant award       284       234    
  Total current liabilities       8,208       4,860    
Long-term debt, net of unamortized deferred costs       31,642       -     
Other long-term liabilities       2,621       90    
  Total liabilities       42,471       4,950    
Total convertible preferred stock       -        97,878    
Total stockholders' equity (deficit)       95,120       (57,830 )  
  Total liabilities, convertible preferred stock and stockholders' equity (deficit)   $   137,591   $   44,998